Download PDF - American College of Chest Physicians

More documents

Recommendations

Info

November was Pulmonary Hypertension Awareness Month.Here’s how you can help.Don’t wait,refer earlysEarly referrals to a PH Specialist help providecomprehensive care 1-3Turn the page to learn about the advantagesof early referrals to PH Specialists… 1,2RVU00224B © 2010 Pfizer Inc. All rights reserved
November was Pulmonary Hypertension Awareness Month.Here’s how you can help.Don’t wait,refer earlyPH Specialists encourage early referrals of PAH patientsregardless of WHO Functional Class (I, II, III, IV)* 1-4Patients receive comprehensive caresA full support system for PAH patients, including comprehensive medical care,reimbursement opportunities, education, and counseling 5-7Patients gain access to information on the latest clinical trials 1-3,5-7sPatients’ participation helps build clinical trials that provide reliable data relevantto the PAH population 1,3,8,9Help optimize care for your PAH patients with early referrals.Please visit www.PHAssociation.org for more information.*Adapted from the New York Heart Association (NYHA).References: 1. Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1)(suppl S):S78–S84. 2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of theAmerican College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with theAmerican College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619.3. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinicalpractice guidelines. Chest. 2007;131:1917–1928. 4. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension:ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S–34S. 5. Temple University Hospital. Temple Lung Center & Pulmonologists. http://pulmonary.templehealth.org/content/default/htm. Accessed September 24, 2010. 6. Stanford University. Stanford Pulmonary Hypertension Program. http://pulmonary.stanford.edu/patientcare/hyperten.html. Accessed September 24, 2010. 7. Pulmonary Hypertension Clinic, Mayo Clinic in Rochester, Minn. Cardiovascular Diseases inMinnesota. http://www.mayoclinic.org/cardiovascular-disease-rst/pulmhyperclinic.html. Accessed September 24, 2010. 8. McLaughlin VV, Badesch DB, Delcroix M, etal. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S97-S107. 9. Humbert M, McLaughlin VV. The 4th WorldSymposium on Pulmonary Hypertension. J Am Coll Cardiol. 2009;54:S1-S2.RVU00224B © 2010 Pfizer Inc. All rights reserved
Page 1: VOL. 6 • NO. 1 • JANUARY 2011Dr
Page 5 and 6: FOR THE TREATMENT OF EXOCRINE PANCR
Page 7 and 8: JANUARY 2011 • CHEST PHYSICIAN CA
Page 9 and 10: JANUARY 2011 • CHEST PHYSICIAN PU
Page 11 and 12: Did you knowREVATIO samples arejust
Page 13 and 14: JANUARY 2011 • CHEST PHYSICIAN PE
Page 15 and 16: JANUARY 2011 • CHEST PHYSICIAN NE
Page 23 and 24: JANUARY 2011 • CHEST PHYSICIAN SL

Download PDF - American College of Chest Physicians

Create successful ePaper yourself

Delete template?

Save as template?